Ascendis Pharma has been granted a patent for a pharmaceutical composition that includes a parathyroid hormone (PTH) compound. The composition is suitable for subcutaneous administration and has a pharmacokinetic profile with a peak to trough ratio of less than 4 within one daily injection interval. The PTH compound is a water-soluble controlled-release PTH compound. GlobalData’s report on Ascendis Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ascendis Pharma, Nanoparticle drug conjugates was a key innovation area identified from patents. Ascendis Pharma's grant share as of September 2023 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11759504B2) discloses a pharmaceutical composition comprising a parathyroid hormone (PTH) compound. The composition is suitable for subcutaneous administration and exhibits a specific pharmacokinetic profile. After subcutaneous administration to a mammal, the PTH compound has a peak to trough ratio of free PTH of less than 4 in plasma within one daily injection interval at steady state. The PTH compound is a water-soluble controlled-release PTH compound of formula (Ia) or a pharmaceutically acceptable salt thereof.
The patent claims also specify various aspects of the pharmaceutical composition. It mentions that the subcutaneous administration is via subcutaneous injection and can be done using a pen device. The peak to trough ratio of the PTH compound is less than 3, indicating a controlled release of the compound. The administration can be to a non-human primate, specifically a cynomolgus monkey, or to a human. The pharmaceutical composition has a pH ranging from and including pH 3 to pH 8, or more specifically, ranging from and including pH 4 to pH 5. Additionally, the patent claims describe the use of a branched polyethylene glycol polymer (-Z) in the composition and specify that it may have one branching point. Furthermore, the patent claims mention the attachment of -L2-L1 to the N-terminal amine functional group of -D in the composition.
This patent provides valuable information about a pharmaceutical composition comprising a PTH compound with specific pharmacokinetic properties. The controlled-release nature of the composition allows for a peak to trough ratio of free PTH of less than 4, indicating a sustained release of the compound. The subcutaneous administration via injection, potentially using a pen device, offers a convenient and efficient method of delivery. The patent also highlights the potential use of the composition in non-human primates, specifically cynomolgus monkeys, and in humans. The specified pH range of the composition ensures its stability and compatibility with biological systems. The incorporation of a branched polyethylene glycol polymer in the composition adds to its controlled-release properties. Overall, this patent presents a novel pharmaceutical composition with potential applications in the field of PTH therapy.
To know more about GlobalData’s detailed insights on Ascendis Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
